Skip to content

A Combined Supplementation of Rosemary and Daylily for Enhancing Sleep Quality in Middle-Aged Adults

A Combined Supplementation of Rosemary and Daylily for Enhancing Sleep Quality in Middle-Aged Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06859879
Acronym
RESTORE-ENG
Enrollment
10
Registered
2025-03-05
Start date
2025-04-15
Completion date
2025-12-15
Last updated
2026-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep

Brief summary

This study aims to investigate the impact of supplementation with two different doses of Rosemary and Daylily herbal extract on various health outcomes in middle-aged adults. Over an eight-week period, the trial will assess improvements in sleep quality, circadian rhythms, energy metabolism, and relevant biochemical markers. The study employs a randomized, placebo-controlled, crossover design to evaluate the efficacy of these supplements in enhancing overall health and well-being.

Interventions

DIETARY_SUPPLEMENTDietary Supplement: low-dose Rosemary and Daylily extract

Supplement containing Rosemary and Daylily extract

DIETARY_SUPPLEMENTDietary Supplement: medium-dose Rosemary and Daylily extract

Supplement containing Rosemary and Daylily extract

DIETARY_SUPPLEMENTDietary Supplement: control

Supplement containing placebo

Sponsors

University of Novi Sad, Faculty of Sport and Physical Education
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age \> 50 years * Trouble falling asleep \> 5 times a month (NHANES criteria) * Body mass index 18.5-29.9 kg/m2 * Free of major chronic diseases or acute disorders * Given written informed consent

Exclusion criteria

* History of dietary supplement use \> 2 weeks before the study commences * Abnormal values for lab clinical chemistry (\> 2 SD) * Unwillingness to return for follow-up analysis * Participation in other clinical trials * Moderate-to-heavy use of alcohol (\> 3 drinks per week)

Design outcomes

Primary

MeasureTime frameDescription
Total sleep timeChange from baseline total sleep time at 8 weeksTotal sleep time measured with actigraph monitor

Secondary

MeasureTime frameDescription
MelatoninChange from baseline serum melatonin at 8 weeksLevel of serum melatonin in serum
Pittsburgh Sleep Quality Index (PSQI)Change from baseline PSQI at 8 weeksThe Pittsburgh Sleep Quality Index (PSQI) is a self-report tool used to assess sleep quality and disturbances. It consists of 19 items covering seven components: sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, daytime dysfunction, and use of sleep medications. Each component is scored from 0 to 3, with higher scores indicating worse sleep quality. The total score ranges from 0 to 21, where a score of 5 or higher suggests poor sleep quality. The PSQI is widely used in clinical and research settings to evaluate sleep health.

Countries

Serbia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026